BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31200360)

  • 1. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 2. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.
    Zhao J; Zheng Z; Han X; Davidoff AJ; Banegas MP; Rai A; Jemal A; Yabroff KR
    Value Health; 2019 Jul; 22(7):762-767. PubMed ID: 31277821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Problem of Cancer Drugs Costs: A Payer Perspective.
    Newcomer LN
    Cancer J; 2020; 26(4):287-291. PubMed ID: 32732670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncology 2020: a drug development and approval paradigm.
    Dhingra K
    Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
    Kelley T
    Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer research: does it deliver for the patient?
    Oldham RK
    Cancer Biother; 1994; 9(2):99-102. PubMed ID: 7812366
    [No Abstract]   [Full Text] [Related]  

  • 9. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 10. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 12. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 13. Key factors impacting the delivery and financing of oncology care in the United States.
    Goldsmith PJ; Paivanas T
    J Natl Compr Canc Netw; 2006 May; 4(5):434-7. PubMed ID: 16715607
    [No Abstract]   [Full Text] [Related]  

  • 14. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
    Lyman GH
    J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
    [No Abstract]   [Full Text] [Related]  

  • 19. The high cost of cancer drugs and what we can do about it.
    Siddiqui M; Rajkumar SV
    Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
    [No Abstract]   [Full Text] [Related]  

  • 20. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.